Literature DB >> 23930191

Close contact precautions could prevent an outbreak of crimean-congo hemorrhagic Fever: a case series report from southern part of tehran.

Masoud Mardani1, Najmeh Namazee.   

Abstract

Between the end of June and the middle of July 2011, an outbreak of Crimean-Congo Hemorrhagic Fever occurred in southern part of Tehran, Iran. This study reports clinical, laboratory findings and outcome of six cases, who were all consanguine. Index case who was livestock-worker died with hemorrhagic manifestations; thereafter his pregnant wife, three brothers, mother-in-law and his pregnant sister-in-law were admitted and except for the latter, ribavirin was administered. The brother with close contact with body fluids and blood of index case, died with hemorrhage. Low platelet, high aminotransferases and elevated PT, PTT were detected in this case. Skin manifestations were present in five cases. Only in one case RT-PCR and IgM serology were reported as positive for CCHF virus by reference laboratory. In endemic areas, high index of suspicion should be kept in mind in successfully finding and treating cases in early phase of the disease.

Entities:  

Keywords:  Crimean-Congo hemorrhagic fever; outbreak; ribavirin prophylaxis; tick-borne disease

Year:  2013        PMID: 23930191      PMCID: PMC3733041     

Source DB:  PubMed          Journal:  Int J Prev Med        ISSN: 2008-7802


INTRODUCTION

Crimean-Congo hemorrhagic fever is a tick-borne viral disease reported from more than 30 countries in Africa, Asia, South-East, Europe, and the Middle East.[1] CCHF was first observed in the Crimea by Russian scientists in 1994.[2] It is a zoonotic viral disease caused by Nairovirus (family Bunyaviridae). The disease has a wide distribution that correlates with the global distribution of Hyalomma tick, the vector responsible for viral transmission.[3] Clinical manifestations are non-specific and may include fever, myalgia, rash and encephalitis. Symptoms typically include high fever, headache, malaise, arthralgia, myalgia, nausea, abdominal pain and non-bloody diarrhea. Early signs typically include fever, hypotension, relative bradycardia, tachypnea, conjunctivitis and pharyngitis.[4] The hemorrhagic phase lasts for 4–5 days and in a majority of the patients it progresses to hemorrhagic diathesis. These include petechia, conjunctival hemorrhage, epistaxis, hematemesis, hemoptysis and melena.[5] Not all the patients develop the classical illness which is fatal in 3–30% of cases.[6] Community-acquired CCHF happens through transmission of virus by direct contact with blood or other infected tissue of livestock or from an infected tick bite.[7] Outbreaks have been reported from neighboring countries, and nosocomial transmission is well described.[89101112] The efficacy of ribavirin in treatment[131415] and prophylaxis[5] for CCHF have been reported. In this study we describe an outbreak and present the clinical, laboratory values and outcome of the six patients with symptoms and signs of CCHF.

CASE REPORT

Case 1

On 25th June 2011 a 24-year-old female, pregnant with gestational age of 16 weeks, presented to the Loghman Hakim Hospital, Tehran, Iran, with chief complaint of hematemesis, petechia on upper extremities and palmar areas. She denied history of vaginal bleeding, fever, myalgia, headache, arthralgia, diarrhea or rectorrhagia. She claimed to have a close contact with her husband who was a livestock-worker and had died the week before, with symptoms of bloody diarrhea and hematemesis. She also had a history of close contact with domestic animals as she worked with her husband. The patient was immediately transferred to an isolated room and serum was obtained for CCHF virus serology and RT-PCR. Her laboratory studies revealed normal aminotransferases and PT, PTT. On baseline laboratory tests, anemia and thrombocytopenia were detected. urine analysis did not show hematuria. Obstetric examinations were normal and sonography showed normal alive twin fetuses. Because of her life-threatening condition, therapeutic ribavirin dose was administered to her. The patient's condition was satisfactory after five days and she was discharged of hospital, with oral ribavirin.

Case 2

On 29th June 2011, a 36-year-old male construction worker presented to the same hospital with chief complaint of fever, malaise, myalgia and headache, ecchymoses and hematemesis unresponsive to conservative managements. His symptoms were started 3 days prior to admission. There was no history of recent travel or direct contact with domestic animals, but a history of contact with his brother's blood and body fluid, who had worked in a live stock and died about 10 days before his admission. On physical examination, the patient was hypotensive (mean arterial blood pressure: 80 mmHg), respiratory rate 36/min and pulse rate 100/min. The patient had yellowish discoloration of sclera, a few petechiae on hard palate and multiple ecchymoses on extremities were detectable. Laboratory tests revealed leukocytosis, thrombocytopenia, increased PT, PTT, INR, aminotransferases, CPK and creatinine. Fluid resuscitation and critical care managements were started. Ribavirin, loading and first doses were administered to him. Serum IgG, IgM ELISA tests and RT-PCR for CCHF virus were obtained. After a few hours of admission, the patient developed intractable hematemesis and epistaxis, not responding to medical managements; the patient's condition deteriorated and finally he died on 30th June, 2011. Surprisingly report of RT-PCR was negative for CCHF virus by reference laboratory. His family members and all close contacts were informed to refer for evaluation. On 30th June, 13 suspicious cases were evaluated, 4 out of 13 were admitted to the hospital and the others who met the criteria for receiving prophylactic ribavirin were discharged with oral ribavirin. They advised to refer to the hospital in case of finding any sign or symptom of CCHF (temperature over 38.5 by mouth, headache, myalgia, petechia, arthralgia, or hemorrhagic manifestations.) Figure 1 shows the consanguinity of these cases.
Figure 1

Organization scheme for the reviewing consanguinity of the cases

Organization scheme for the reviewing consanguinity of the cases

Case 3

This 41-year-old male construction worker, whose two brothers had died, denied any symptoms of fever, myalgia headache or abdominal pain, but on physical examination there were a few petechiae on buccal mucosa. He had neither close contact with his two dead brothers nor history of contact with domestic animals. Laboratory studies were within normal values. Empirical ribavirin was started for him with therapeutic dose. His serum was obtained for evaluation of CCHF virus. He was discharged of hospital after 5 days without any complications, with oral ribavirin. His report of RT-PCR for CCHF virus was negative.

Case 4

A 27-year-old male florist whose two brothers had died also was admitted with mild fever without any history of myalgia, arthralgia headache or bleeding. He did not recall close contact with his brothers or domestic animals. On physical examination he showed mild fever and petechia on hard palate. Laboratory tests were all reported within normal values. RT-PCR was reported negative for CCHF virus. Ribavirin was administered to him and he was also discharged from hospital with satisfactory condition.

Case 5

This 50-year-old female housewife, whose son-in-law (index case) had died, was admitted with suspicious symptoms and signs of CCHF. She claimed to have experienced myalgia, headache and fever. She had developed arthralgia, especially in both knees and shoulders a few days before admission. The patient had history of close contact with her daughter and her dead son-in-law. Physical examinations revealed oral temperature of 38.5 and petechia on hard palate. Laboratory tests showed mildly increased PT, INR and creatinine. Anemia and leukopenia were notable in baseline tests. She also received ribavirin and became afebrile after 4 days. Platelet levels came into normal limits after 4 days ELISA IgM antibody and RT-PCR for CCHF virus were reported as positive in this patient by reference laboratory. Her general condition showed improvement. The patient preferred to leave out the hospital the sixth day of treatment, so oral ribavirin was prescribed for her for the rest of treatment period.

Case 6

This 29-year-old pregnant female with gestational age of 32 weeks, whose two brothers-in-law had died, was admitted for better evaluation. She denied any history of bleeding, myalgia, arthralgia or fever. Physical examination and laboratory findings were all normal. Obstetric examination and sonography showed normal alive fetus. The patient only was observed and was discharged after 3 days. Her RT-PCR was reported negative for CCHF virus.

DISCUSSION

The first confirmed outbreak of CCHF in Iran was reported in June 1999.[16] After that multiple reports from a few provinces showed that Iran should be known as an endemic area for CCHF. In our case study all patients who were consanguine and had Afghan nationality, were living in Iran for a long time. The pregnant woman whose husband (index case) had died with hemorrhagic manifestations presented with suspicious signs and symptoms and received ribavirin. The use of ribavirin is now well established in most countries where CCHF is endemic.[15] Case 2, who had history of close contact with his brother's blood and body fluids, presented with hematemesis, bloody diarrhea and ecchymoses. The patient received loading and first dose of ribavirin, but ribavirin was administered to him when hemorrhagic manifestations had been established. Superior efficacy of early initiation of ribavirin has been discussed in different surveys.[1718] Investigations among 13 consanguine cases revealed four high risk cases who were admitted to the hospital. The others who met the criteria were administered prophylactics ribavirin and advised to refer in case of alarming signs and symptoms. These signs and symptoms have been discussed in a study by Ertugrul et al.[9] In this outbreak the index case was a livestock worker who had history of contact with illegally imported cattles from the southeastern neighboring countries (Pakistan). There are some reports of CCHF outbreaks in southeastern neighboring countries.[10] In physical examination of the patients who were admitted skin manifestations especially petechia were present in 5 out of 6 and were the most common signs of the patients. Laboratory findings showed thrombocytopenia in two and leukopenia / leukocytosis each in one case. Demographic, clinical characteristics and laboratory values have been shown in Tables 1–3.
Table 1

Clinical manifestations, risk factors and outcome of cases

Table 3

Baseline laboratory studies of admitted cases

Clinical manifestations, risk factors and outcome of cases Demograaphic, clinical characteristics and outcome for the admitted patients Baseline laboratory studies of admitted cases PT, PTT, low platelet, aminotransferases rising and leukocytosis were all presented in case two and close contact with index case's body fluids and experienced severe disease and finally died. His outcome and laboratory findings reveal the importance of finding and treating the patients in early phase, and also the importance of contact prevention. For the individual, use of effective personal protective measures against tick bites and limiting animal exposure are the best ways to avoid the infection.[19] In this study two pregnant women were presented, one of them treated with ribavirin due to high index of clinical suspicion, high illness to infection ratio of CCHF and high mortality. A suspected patient should be placed in a private room, and negative-pressure respiratory isolation should be considered, particularly if coughing, vomiting, or other activities generating large-droplet aerosols occur. Those entering the patient's room should wear gloves and gowns, and those approaching within meter should wear face shields or surgical masks and eye protection to prevent contact with blood or other body fluids.[19] As there is evidence on the effectiveness of preventive interventions and a significant reduction in mortality[20] ,preventive attempts, play an important role in reducing transmission of this highly contagious disease. This study only described manifestations, management and outcome of the cases in an outbreak. Larger and controlled studies are needed to evaluate the various aspects of the disease.
Table 2

Demograaphic, clinical characteristics and outcome for the admitted patients

  17 in total

1.  Short report: Crimean-Congo hemorrhagic fever outbreak in Rawalpindi, Pakistan, February 2002.

Authors:  Muhammad Nauman Athar; Haider Zaigham Baqai; Masood Ahmad; Mohammad Ali Khalid; Naghman Bashir; Ahsan Maqbool Ahmad; Abbas Hayat Balouch; Kaukab Bashir
Journal:  Am J Trop Med Hyg       Date:  2003-09       Impact factor: 2.345

2.  The role of ribavirin in the therapy of Crimean-Congo hemorrhagic fever: early use is promising.

Authors:  N Tasdelen Fisgin; O Ergonul; L Doganci; N Tulek
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-03-20       Impact factor: 3.267

Review 3.  Crimean-Congo hemorrhagic fever: current and future prospects of vaccines and therapies.

Authors:  Maryam Keshtkar-Jahromi; Jens H Kuhn; Iva Christova; Steven B Bradfute; Peter B Jahrling; Sina Bavari
Journal:  Antiviral Res       Date:  2011-03-06       Impact factor: 5.970

Review 4.  Ribavirin for Crimean-Congo hemorrhagic fever: systematic review and meta-analysis.

Authors:  Karla Soares-Weiser; Sherine Thomas; Gail Thomson; Paul Garner
Journal:  BMC Infect Dis       Date:  2010-07-13       Impact factor: 3.090

5.  Crimean-Congo hemorrhagic fever virus as a nosocomial pathogen in Iran.

Authors:  Masoud Mardani; Maryam Keshtkar-Jahromi; Behrooz Ataie; Peyman Adibi
Journal:  Am J Trop Med Hyg       Date:  2009-10       Impact factor: 2.345

Review 6.  Crimean-Congo hemorrhagic fever.

Authors:  Masoud Mardani; Maryam Keshtkar-Jahromi
Journal:  Arch Iran Med       Date:  2007-04       Impact factor: 1.354

7.  Knowledge and attitude toward Crimean-Congo haemorrhagic fever in occupationally at-risk Iranian healthcare workers.

Authors:  M Rahnavardi; M Rajaeinejad; F Pourmalek; M Mardani; K Holakouie-Naieni; S Dowlatshahi
Journal:  J Hosp Infect       Date:  2008-05       Impact factor: 3.926

8.  The efficacy of oral ribavirin in the treatment of crimean-congo hemorrhagic fever in Iran.

Authors:  M Mardani; M Keshtkar Jahromi; K Holakouie Naieni; M Zeinali
Journal:  Clin Infect Dis       Date:  2003-06-04       Impact factor: 9.079

9.  Isn't it the Time for Working on Public Health Guidance in Health System of Iran?

Authors:  Laleh Ghadirian; Azadeh Sayarifard
Journal:  Int J Prev Med       Date:  2013-02

10.  An update on crimean congo hemorrhagic Fever.

Authors:  Suma B Appannanavar; Baijayantimala Mishra
Journal:  J Glob Infect Dis       Date:  2011-07
View more
  4 in total

1.  The effect of inflammatory cytokines and the level of vitamin D on prognosis in Crimean-Congo hemorrhagic fever.

Authors:  Emine Parlak; Ayşe Ertürk; Yasemin Çağ; Engin Sebin; Musa Gümüşdere
Journal:  Int J Clin Exp Med       Date:  2015-10-15

2.  Nosocomial infection of CCHF among health care workers in Rajasthan, India.

Authors:  Pragya D Yadav; Deepak Y Patil; Anita M Shete; Prasad Kokate; Pulkit Goyal; Santosh Jadhav; Sanjeev Sinha; Divya Zawar; Surendra K Sharma; Arti Kapil; D K Sharma; Kamlesh J Upadhyay; Devendra T Mourya
Journal:  BMC Infect Dis       Date:  2016-11-03       Impact factor: 3.090

Review 3.  Crimean-Congo hemorrhagic fever in pregnancy: A systematic review and case series from Russia, Kazakhstan and Turkey.

Authors:  Natalia Yurievna Pshenichnaya; Hakan Leblebicioglu; Ilkay Bozkurt; Irina Viktorovna Sannikova; Gulzhan Narkenovna Abuova; Andrey Sergeevich Zhuravlev; Sener Barut; Mutabar Bekovna Shermetova; Tom E Fletcher
Journal:  Int J Infect Dis       Date:  2017-02-27       Impact factor: 3.623

Review 4.  Ribavirin for treating Crimean Congo haemorrhagic fever.

Authors:  Samuel Johnson; Nicholas Henschke; Nicola Maayan; Inga Mills; Brian S Buckley; Artemisia Kakourou; Rachel Marshall
Journal:  Cochrane Database Syst Rev       Date:  2018-06-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.